April 2026 did not reopen the UK M&A market in full. Capital moved where boards could underwrite reserve life, recurring savings assets, testing and assurance positions, defence supply exposure, and specialist healthcare demand. The month’s largest stories sat in energy, pensions and retirement, industrial aerospace, and healthcare — sectors where scale and resilience still drew decisive bids.
Office for National Statistics data published on 3 March showed inward M&A value rising to £27.4bn in Q4 2025, while domestic deal value fell to £1.8bn, the lowest since Q2 2020. The same bulletin quoted the Bank of England’s Agents summary: “Mergers and acquisitions activity remains subdued, with deals taking longer due to increased due diligence and regulatory uncertainty”. By April, that caution was still present, but it sat alongside a willingness to move on assets that were hard to replicate and straightforward to defend in the boardroom.
The deals that defined April 2026 —
Shell buys reserve depth in Canada —
Shell’s $16.4bn agreement to acquire Canada’s ARC Resources was the largest UK-linked transaction of the month by a wide margin. Shell said ARC would add 370,000 barrels of oil equivalent a day to output, add 2 billion barrels of reserves, and generate around $250m of savings within a year of closing. The group also lifted its compound annual production growth target for the decade from 1% to 4%.
The deal gives Shell greater depth in Canada and a stronger position around LNG. Wael Sawan told reporters: “We are very comfortable with what this (deal) does for our financial framework.” Shell shares still fell 2.1% on the day, a reminder that size alone does not settle investor questions on capital discipline.
EQT pushes at Intertek’s valuation —
EQT’s pursuit of Intertek became April’s clearest London-listed bid story. Intertek rejected an initial 51.5 pound-a-share proposal on 16 April, valuing the testing company at about £7.93bn. A revised 54 pound-a-share offer, valuing the business at about £8.3bn, was also rejected on 24 April, with Reuters reporting that EQT was considering a third bid.
Intertek answered the pressure with its own plan. Alongside rejecting the offer, the company said it would explore separating its energy and infrastructure activities from its testing and assurance operations. The bid put a number on what a buyer thought the business was worth. Intertek’s response was to argue that the quoted structure was not the only path to value. This revised offer would have ranked as the UK’s second-largest private equity take-private on record if completed.
Standard Life builds scale in retirement —
On 15 April, Standard Life agreed to acquire Aegon’s UK business for £2bn in cash and shares. The transaction will expand the combined group to 16 million customers and lift managed assets by 50% to £480bn. Aegon will also become Standard Life’s largest shareholder with a 15.3% stake, and Standard Life said the deal should generate around £800m of cost and capital synergies.
The acquisition adds customer scale, retirement assets, and a stronger position in a market built around long-duration relationships and recurring savings flows. Andy Briggs said: “This makes us by some margin the market leader in the fast-growing UK savings and retirement markets.”
In a month defined by selective confidence, this was one of the clearest examples of acquisition as business-model reinforcement rather than simple expansion.
Senior draws defence-linked interest —
Senior’s agreed £1.4bn sale to Tinicum and Blackstone, announced on 7 April, brought aerospace and defence into the centre of April’s deal flow. The consortium’s 300 pence-a-share cash offer followed months of interest in the British aerospace and defence supplier.
The offer pointed to a more selective pattern in overseas interest. Buyers were not scanning British industrial companies indiscriminately. They were moving on businesses tied to aerospace build rates, defence procurement, and specialised manufacturing positions. Tinicum said “the consortium has conviction in Senior and its growth potential,” and also set out plans to merge AeroFlow Technologies with Senior if the acquisition completes.
Advanced Medical Solutions joins the bid wave —
Advanced Medical Solutions rounded out the month’s top five. On 20 April, the British wound-care and surgical products company said it was in talks with TA Associates over a possible takeover. TA was reportedly preparing a 280 pence-a-share offer, valuing the business at more than £600m, and the bidder had until 16 May to announce a firm intention to make an offer or walk away under the Takeover Code.
The approach sat below the month’s megadeals in headline size, but it fitted the same pattern. Sponsor interest in London-listed companies was not confined to the largest names or the most visible sectors. It extended to specialist healthcare businesses with defensible product positions and dependable end demand. Advanced Medical Solutions showed how quickly a mid-cap UK company can become part of the wider valuation debate around the London market.
The bottom line —
April’s deal flow was narrow, but it was not thin. Buyers with capital stayed active where they could secure something durable: reserves that extend production, assets that deepen retirement exposure, engineering capability linked to aerospace and defence, testing platforms with global relevance, and healthcare products with specialist demand. The market did not reward breadth. It rewarded conviction.
The UK remained attractive to two kinds of acquirer. Strategic buyers moved when an acquisition strengthened a long-term operating model. Private equity pressed where London valuations looked light against underlying cash generation or strategic value. Boards that can explain their worth clearly, defend it under scrutiny, and move quickly when circumstances change are in the strongest position. April did not point to exuberance. It pointed to a market where capital is available, but only for assets with staying power, strategic utility, and a clear route to value creation.
Four takeaways —
- Decide whether the market is underpricing your business — and whether you can prove it. Intertek’s April story turned on the gap between public-market value and what a buyer was prepared to pay. Portfolio choices, capital allocation, operational priorities, and any credible separation logic need to be ready before an approach lands.
- Keep transaction readiness current. Senior and Advanced Medical Solutions showed how quickly a process can move once interest becomes public. Decision rights, shareholder mapping, data-room discipline, forecasting, and communications planning shape leverage from day one.
- Favour deals with one clear sentence behind them. Shell bought reserves, output, and LNG adjacency. Standard Life bought customer scale, assets, and a stronger retirement-savings position. The strongest April transactions were easy to explain because the underlying economics were easy to follow.
- Resilience is carrying a premium. April’s buyers focused on energy security, retirement savings, quality assurance, defence supply, and specialist healthcare. These are different markets, but they share the same attraction: they are easier to underwrite in a volatile environment.
You must be logged in to post a comment.